|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0280100,
umls-concept:C0332173,
umls-concept:C0439228,
umls-concept:C0442027,
umls-concept:C0920321,
umls-concept:C0935763,
umls-concept:C1134654,
umls-concept:C1521725,
umls-concept:C1521801,
umls-concept:C1527415,
umls-concept:C1563758
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-2-18
|
|
pubmed:abstractText |
To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AdamsonPeter CPC,
pubmed-author:BalisFrank MFM,
pubmed-author:CohnSusan LSL,
pubmed-author:FoutsMolly EME,
pubmed-author:FoxElizabethE,
pubmed-author:GoodspeedWendyW,
pubmed-author:GoodwinAnneA,
pubmed-author:HageyAnne EAE,
pubmed-author:KrivoshikAndrewA,
pubmed-author:KromplewskiMarieM,
pubmed-author:MarisJohn MJM,
pubmed-author:MedinaDianeD,
pubmed-author:WidemannBrigitte CBC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1111-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18281544-Adolescent,
pubmed-meshheading:18281544-Antineoplastic Agents,
pubmed-meshheading:18281544-Child,
pubmed-meshheading:18281544-Child, Preschool,
pubmed-meshheading:18281544-Dose-Response Relationship, Drug,
pubmed-meshheading:18281544-Humans,
pubmed-meshheading:18281544-Maximum Tolerated Dose,
pubmed-meshheading:18281544-Neoplasm Recurrence, Local,
pubmed-meshheading:18281544-Neoplasms,
pubmed-meshheading:18281544-Sulfonamides,
pubmed-meshheading:18281544-Tubulin Modulators
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
|
|
pubmed:affiliation |
Authors' Affiliations: Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. foxb@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I,
Research Support, N.I.H., Intramural
|
